Abstract
First case of infective endocarditis on a percutaneous aortic valve replacement due to Moraxalla nonliquefaciens in 64 year old woman. It was successfully treated medically with antibiotics. She had not suitable for surgical aortic valve replacement due to 3 sternotomies for thymoma resection and subsequent radiotherapy with blocked major thoracic veins. Due to her azathioprine immunosuppresion (myasthenia) she may have been at increased endocarditis risk. We suggest prophylactic antibiotics at implant for this group in future.
Copyright © 2011 Elsevier Inc. All rights reserved.
MeSH terms
-
Anti-Bacterial Agents / therapeutic use
-
Aortic Valve Stenosis / therapy*
-
Azathioprine / adverse effects
-
Cardiac Catheterization / adverse effects*
-
Cardiac Catheterization / instrumentation
-
Endocarditis, Bacterial / drug therapy
-
Endocarditis, Bacterial / microbiology*
-
Female
-
Heart Valve Prosthesis / adverse effects*
-
Heart Valve Prosthesis Implantation / adverse effects*
-
Heart Valve Prosthesis Implantation / instrumentation
-
Humans
-
Immunosuppressive Agents / adverse effects
-
Middle Aged
-
Moraxella / pathogenicity*
-
Moraxellaceae Infections / drug therapy
-
Moraxellaceae Infections / microbiology*
-
Myasthenia Gravis / drug therapy
-
Prosthesis-Related Infections / drug therapy
-
Prosthesis-Related Infections / microbiology*
-
Risk Factors
-
Treatment Outcome
Substances
-
Anti-Bacterial Agents
-
Immunosuppressive Agents
-
Azathioprine